For example, HER2+ breast cancer patients with isolated brain metastases or synchronous but stable extracranial disease may live 5 years or more with multi-modal treatment, while those with triple-negative breast cancer (TNBC), non-small cell lung carcinoma (NSCLC) and melanoma typically succumb within 12 months, even with aggressive treatment. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.